ID   DPOE1_HUMAN             Reviewed;        2286 AA.
AC   Q07864; Q13533; Q86VH9;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 5.
DT   12-APR-2017, entry version 175.
DE   RecName: Full=DNA polymerase epsilon catalytic subunit A;
DE            EC=2.7.7.7;
DE   AltName: Full=DNA polymerase II subunit A;
GN   Name=POLE; Synonyms=POLE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 48-51; 876-886 AND
RP   1338-1344.
RC   TISSUE=T-cell;
RX   PubMed=8486689;
RA   Kesti T., Frantti H., Syvaeoja J.E.;
RT   "Molecular cloning of the cDNA for the catalytic subunit of human DNA
RT   polymerase epsilon.";
RL   J. Biol. Chem. 268:10238-10245(1993).
RN   [2]
RP   SEQUENCE REVISION.
RA   Syvaeoja J.E.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Asahara H., Goldsmith J.S., Lee E., Linn S.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-2286.
RG   NIEHS SNPs program;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   IDENTIFICATION IN EPSILON DNA POLYMERASE COMPLEX.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10801849; DOI=10.1074/jbc.M002548200;
RA   Li Y., Pursell Z.F., Linn S.;
RT   "Identification and cloning of two histone fold motif-containing
RT   subunits of HeLa DNA polymerase epsilon.";
RL   J. Biol. Chem. 275:23247-23252(2000).
RN   [6]
RP   INTERACTION WITH TOPBP1.
RX   PubMed=11395493; DOI=10.1074/jbc.M102245200;
RA   Maekiniemi M., Hillukkala T., Tuusa J., Reini K., Vaara M., Huang D.,
RA   Pospiech H., Majuri I., Westerling T., Maekelae T.P., Syvaeoja J.E.;
RT   "BRCT domain-containing protein TopBP1 functions in DNA replication
RT   and damage response.";
RL   J. Biol. Chem. 276:30399-30406(2001).
RN   [7]
RP   INTERACTION WITH RAD17.
RX   PubMed=14500819; DOI=10.1093/nar/gkg765;
RA   Post S.M., Tomkinson A.E., Lee E.Y.-H.P.;
RT   "The human checkpoint Rad protein Rad17 is chromatin-associated
RT   throughout the cell cycle, localizes to DNA replication sites, and
RT   interacts with DNA polymerase epsilon.";
RL   Nucleic Acids Res. 31:5568-5575(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1940, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1184, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   INVOLVEMENT IN FILS.
RX   PubMed=23230001; DOI=10.1084/jem.20121303;
RA   Pachlopnik Schmid J., Lemoine R., Nehme N., Cormier-Daire V., Revy P.,
RA   Debeurme F., Debre M., Nitschke P., Bole-Feysot C., Legeai-Mallet L.,
RA   Lim A., de Villartay J.P., Picard C., Durandy A., Fischer A.,
RA   de Saint Basile G.;
RT   "Polymerase epsilon1 mutation in a human syndrome with facial
RT   dysmorphism, immunodeficiency, livedo, and short stature (FILS
RT   syndrome).";
RL   J. Exp. Med. 209:2323-2330(2012).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1297 AND SER-1317, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   VARIANTS CRCS12 LEU-411 AND VAL-424, AND VARIANTS THR-189; HIS-231;
RP   HIS-286; SER-367; ARG-436; PHE-459; TRP-762; ASN-777; ASN-1008;
RP   VAL-1255; MET-1368; SER-1421; ASN-1752; ASN-2013; THR-2056 AND
RP   VAL-2213.
RX   PubMed=23263490; DOI=10.1038/ng.2503;
RG   CORGI Consortium;
RG   WGS500 Consortium;
RA   Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M.,
RA   Broderick P., Kemp Z., Spain S.L., Guarino Almeida E., Salguero I.,
RA   Sherborne A., Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K.,
RA   Dobbins S., Barclay E., Gorman M., Martin L., Kovac M.B., Humphray S.,
RA   Lucassen A., Holmes C.C., Bentley D., Donnelly P., Taylor J.,
RA   Petridis C., Roylance R., Sawyer E.J., Kerr D.J., Clark S., Grimes J.,
RA   Kearsey S.E., Thomas H.J., McVean G., Houlston R.S., Tomlinson I.;
RT   "Germline mutations affecting the proofreading domains of POLE and
RT   POLD1 predispose to colorectal adenomas and carcinomas.";
RL   Nat. Genet. 45:136-144(2013).
RN   [14]
RP   VARIANT CRCS12 VAL-424.
RX   PubMed=24501277; DOI=10.1093/hmg/ddu058;
RA   Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A.,
RA   Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C.,
RA   Juarez M., Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A.,
RA   Juan M.J., Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R.,
RA   Lazaro C., Capella G., Pineda M., Soto J.L., Blanco I.;
RT   "New insights into POLE and POLD1 germline mutations in familial
RT   colorectal cancer and polyposis.";
RL   Hum. Mol. Genet. 23:3506-3512(2014).
RN   [15]
RP   VARIANT CRCS12 PHE-458.
RX   PubMed=25860647; DOI=10.1007/s10689-015-9803-2;
RA   Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E.,
RA   Steinsbekk K.S., Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.;
RT   "A novel POLE mutation associated with cancers of colon, pancreas,
RT   ovaries and small intestine.";
RL   Fam. Cancer 14:437-448(2015).
RN   [16]
RP   VARIANT CRCS12 LEU-411.
RX   PubMed=27573199; DOI=10.1007/s10689-016-9925-1;
RA   Wimmer K., Beilken A., Nustede R., Ripperger T., Lamottke B., Ure B.,
RA   Steinmann D., Reineke-Plaass T., Lehmann U., Zschocke J., Valle L.,
RA   Fauth C., Kratz C.P.;
RT   "A novel germline POLE mutation causes an early onset cancer prone
RT   syndrome mimicking constitutional mismatch repair deficiency.";
RL   Fam. Cancer 16:67-71(2017).
RN   [17]
RP   VARIANTS ARG-286; CYS-1382 AND THR-1925.
RX   PubMed=27612425; DOI=10.18632/oncotarget.11862;
RA   Ahn S.M., Ansari A.A., Kim J., Kim D., Chun S.M., Kim J., Kim T.W.,
RA   Park I., Yu C.S., Jang S.J.;
RT   "The somatic POLE P286R mutation defines a unique subclass of
RT   colorectal cancer featuring hypermutation, representing a potential
RT   genomic biomarker for immunotherapy.";
RL   Oncotarget 7:68638-68649(2016).
CC   -!- FUNCTION: Participates in DNA repair and in chromosomal DNA
CC       replication.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1).
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883;
CC         Evidence={ECO:0000250};
CC       Note=Binds 1 [4Fe-4S] cluster. {ECO:0000250};
CC   -!- SUBUNIT: Catalytic and central component of the epsilon DNA
CC       polymerase complex consisting of four subunits: POLE, POLE2, POLE3
CC       and POLE4. Interacts with RAD17 and TOPBP1.
CC       {ECO:0000269|PubMed:10801849, ECO:0000269|PubMed:11395493,
CC       ECO:0000269|PubMed:14500819}.
CC   -!- INTERACTION:
CC       P56282:POLE2; NbExp=3; IntAct=EBI-348526, EBI-713847;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- DOMAIN: The DNA polymerase activity domain resides in the N-
CC       terminal half of the protein, while the C-terminus is necessary
CC       for complexing subunits B and C. The C-terminus may also regulate
CC       the catalytic activities of the enzyme.
CC   -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for
CC       the formation of polymerase complexes. {ECO:0000250}.
CC   -!- DISEASE: Colorectal cancer 12 (CRCS12) [MIM:615083]: A complex
CC       disease characterized by malignant lesions arising from the inner
CC       wall of the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       CRCS12 is characterized by a high-penetrance predisposition to the
CC       development of colorectal adenomas and carcinomas, with a variable
CC       tendency to develop multiple and large tumors. Onset is usually
CC       before age 40 years. The histologic features of the tumors are
CC       unremarkable. {ECO:0000269|PubMed:23263490,
CC       ECO:0000269|PubMed:24501277, ECO:0000269|PubMed:25860647,
CC       ECO:0000269|PubMed:27573199}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Facial dysmorphism, immunodeficiency, livedo, and short
CC       stature (FILS) [MIM:615139]: A syndrome characterized by mild
CC       facial dysmorphism, mainly malar hypoplasia, livedo on the skin
CC       since birth, and immunodeficiency resulting in recurrent
CC       infections. Growth impairment is observed during early childhood
CC       and results in variable short stature in adulthood.
CC       {ECO:0000269|PubMed:23230001}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-B family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA15448.1; Type=Frameshift; Positions=443, 448; Evidence={ECO:0000305};
CC       Sequence=AAA15448.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pole/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S60080; AAA15448.1; ALT_SEQ; mRNA.
DR   EMBL; L09561; AAC19148.1; -; mRNA.
DR   EMBL; U49356; AAA90924.1; -; mRNA.
DR   EMBL; AY273166; AAP12650.1; -; Genomic_DNA.
DR   CCDS; CCDS9278.1; -.
DR   PIR; G02434; G02434.
DR   RefSeq; NP_006222.2; NM_006231.3.
DR   UniGene; Hs.524871; -.
DR   ProteinModelPortal; Q07864; -.
DR   SMR; Q07864; -.
DR   BioGrid; 111422; 47.
DR   DIP; DIP-24243N; -.
DR   IntAct; Q07864; 17.
DR   MINT; MINT-145475; -.
DR   STRING; 9606.ENSP00000322570; -.
DR   ChEMBL; CHEMBL2363042; -.
DR   DrugBank; DB00242; Cladribine.
DR   iPTMnet; Q07864; -.
DR   PhosphoSitePlus; Q07864; -.
DR   BioMuta; POLE; -.
DR   DMDM; 116241339; -.
DR   EPD; Q07864; -.
DR   MaxQB; Q07864; -.
DR   PaxDb; Q07864; -.
DR   PeptideAtlas; Q07864; -.
DR   PRIDE; Q07864; -.
DR   DNASU; 5426; -.
DR   Ensembl; ENST00000320574; ENSP00000322570; ENSG00000177084.
DR   GeneID; 5426; -.
DR   KEGG; hsa:5426; -.
DR   UCSC; uc001uks.3; human.
DR   CTD; 5426; -.
DR   DisGeNET; 5426; -.
DR   GeneCards; POLE; -.
DR   H-InvDB; HIX0022184; -.
DR   HGNC; HGNC:9177; POLE.
DR   HPA; HPA058210; -.
DR   HPA; HPA067385; -.
DR   MalaCards; POLE; -.
DR   MIM; 174762; gene.
DR   MIM; 615083; phenotype.
DR   MIM; 615139; phenotype.
DR   neXtProt; NX_Q07864; -.
DR   OpenTargets; ENSG00000177084; -.
DR   Orphanet; 352712; Facial dysmorphism - immunodeficiency - livedo - short stature.
DR   PharmGKB; PA277; -.
DR   eggNOG; KOG1798; Eukaryota.
DR   eggNOG; COG0417; LUCA.
DR   GeneTree; ENSGT00390000010194; -.
DR   HOVERGEN; HBG051398; -.
DR   InParanoid; Q07864; -.
DR   KO; K02324; -.
DR   OMA; QLGCVCM; -.
DR   OrthoDB; EOG091G006J; -.
DR   PhylomeDB; Q07864; -.
DR   TreeFam; TF105017; -.
DR   Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex.
DR   Reactome; R-HSA-174430; Telomere C-strand synthesis initiation.
DR   Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-5656169; Termination of translesion DNA synthesis.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-68952; DNA replication initiation.
DR   Reactome; R-HSA-68962; Activation of the pre-replicative complex.
DR   ChiTaRS; POLE; human.
DR   GeneWiki; POLE_(enzyme); -.
DR   GenomeRNAi; 5426; -.
DR   PRO; PR:Q07864; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000177084; -.
DR   CleanEx; HS_POLE; -.
DR   ExpressionAtlas; Q07864; baseline and differential.
DR   Genevisible; Q07864; HS.
DR   GO; GO:0008622; C:epsilon DNA polymerase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IEA:InterPro.
DR   GO; GO:0008310; F:single-stranded DNA 3'-5' exodeoxyribonuclease activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; IMP:UniProtKB.
DR   GO; GO:0006270; P:DNA replication initiation; TAS:Reactome.
DR   GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; IMP:UniProtKB.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0006272; P:leading strand elongation; IBA:GO_Central.
DR   GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB.
DR   GO; GO:0000722; P:telomere maintenance via recombination; TAS:Reactome.
DR   Gene3D; 3.30.420.10; -; 1.
DR   Gene3D; 3.90.1600.10; -; 2.
DR   InterPro; IPR006172; DNA-dir_DNA_pol_B.
DR   InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc.
DR   InterPro; IPR006134; DNA-dir_DNA_pol_B_multi_dom.
DR   InterPro; IPR013697; DNA_pol_e_suA_C.
DR   InterPro; IPR023211; DNA_pol_palm_dom.
DR   InterPro; IPR029703; POL2.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   PANTHER; PTHR10670; PTHR10670; 1.
DR   Pfam; PF00136; DNA_pol_B; 1.
DR   Pfam; PF03104; DNA_pol_B_exo1; 1.
DR   Pfam; PF08490; DUF1744; 1.
DR   SMART; SM01159; DUF1744; 1.
DR   SMART; SM00486; POLBc; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
PE   1: Evidence at protein level;
KW   4Fe-4S; Complete proteome; Direct protein sequencing;
KW   Disease mutation; DNA damage; DNA repair; DNA replication;
KW   DNA-binding; DNA-directed DNA polymerase; Iron; Iron-sulfur;
KW   Metal-binding; Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1   2286       DNA polymerase epsilon catalytic subunit
FT                                A.
FT                                /FTId=PRO_0000046455.
FT   ZN_FING    2158   2190       CysA-type.
FT   MOTIF      2221   2238       CysB motif.
FT   METAL      2158   2158       Zinc. {ECO:0000250}.
FT   METAL      2161   2161       Zinc. {ECO:0000250}.
FT   METAL      2187   2187       Zinc. {ECO:0000250}.
FT   METAL      2190   2190       Zinc. {ECO:0000250}.
FT   METAL      2221   2221       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      2224   2224       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      2236   2236       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      2238   2238       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   MOD_RES    1184   1184       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1297   1297       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1317   1317       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1940   1940       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   VARIANT      31     31       A -> S (in dbSNP:rs34047482).
FT                                /FTId=VAR_061138.
FT   VARIANT      99     99       P -> L (in dbSNP:rs5744739).
FT                                /FTId=VAR_028429.
FT   VARIANT     189    189       A -> T (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069339.
FT   VARIANT     231    231       R -> H (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069340.
FT   VARIANT     252    252       A -> V (in dbSNP:rs5744751).
FT                                /FTId=VAR_020276.
FT   VARIANT     260    260       R -> Q (in dbSNP:rs5744752).
FT                                /FTId=VAR_028430.
FT   VARIANT     286    286       P -> H (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069341.
FT   VARIANT     286    286       P -> R (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:27612425}.
FT                                /FTId=VAR_077349.
FT   VARIANT     336    336       N -> S (in dbSNP:rs5744760).
FT                                /FTId=VAR_020277.
FT   VARIANT     367    367       F -> S (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069342.
FT   VARIANT     411    411       V -> L (in CRCS12; associated with
FT                                disease susceptibility).
FT                                {ECO:0000269|PubMed:23263490,
FT                                ECO:0000269|PubMed:27573199}.
FT                                /FTId=VAR_069343.
FT   VARIANT     424    424       L -> V (in CRCS12; associated with
FT                                disease susceptibility;
FT                                dbSNP:rs483352909).
FT                                {ECO:0000269|PubMed:23263490,
FT                                ECO:0000269|PubMed:24501277}.
FT                                /FTId=VAR_069344.
FT   VARIANT     436    436       P -> R (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs864622766).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069345.
FT   VARIANT     458    458       Y -> F (in CRCS12).
FT                                {ECO:0000269|PubMed:25860647}.
FT                                /FTId=VAR_077350.
FT   VARIANT     459    459       S -> F (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069346.
FT   VARIANT     695    695       F -> I (in dbSNP:rs5744799).
FT                                /FTId=VAR_020278.
FT   VARIANT     762    762       R -> W (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069347.
FT   VARIANT     777    777       K -> N (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069348.
FT   VARIANT    1008   1008       K -> N (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069349.
FT   VARIANT    1255   1255       L -> V (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069350.
FT   VARIANT    1368   1368       V -> M (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs770558983).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069351.
FT   VARIANT    1382   1382       R -> C (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs5744904).
FT                                {ECO:0000269|PubMed:27612425}.
FT                                /FTId=VAR_028431.
FT   VARIANT    1395   1395       Y -> C (in dbSNP:rs5744933).
FT                                /FTId=VAR_020279.
FT   VARIANT    1396   1396       N -> S (in dbSNP:rs5744934).
FT                                /FTId=VAR_020280.
FT   VARIANT    1399   1399       E -> Q (in dbSNP:rs5744935).
FT                                /FTId=VAR_020281.
FT   VARIANT    1421   1421       P -> S. {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069352.
FT   VARIANT    1577   1577       E -> A (in dbSNP:rs5744948).
FT                                /FTId=VAR_028432.
FT   VARIANT    1712   1712       A -> V (in dbSNP:rs5744950).
FT                                /FTId=VAR_028433.
FT   VARIANT    1752   1752       D -> N (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069353.
FT   VARIANT    1857   1857       K -> R (in dbSNP:rs5744971).
FT                                /FTId=VAR_028434.
FT   VARIANT    1925   1925       I -> T (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:27612425}.
FT                                /FTId=VAR_077351.
FT   VARIANT    1935   1935       C -> Y (in dbSNP:rs5744991).
FT                                /FTId=VAR_028435.
FT   VARIANT    2013   2013       D -> N. {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069354.
FT   VARIANT    2040   2040       A -> V (in dbSNP:rs5745021).
FT                                /FTId=VAR_020282.
FT   VARIANT    2056   2056       A -> T (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs58916399).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069355.
FT   VARIANT    2140   2140       E -> K (in dbSNP:rs5745066).
FT                                /FTId=VAR_048881.
FT   VARIANT    2159   2159       R -> C (in dbSNP:rs5745067).
FT                                /FTId=VAR_048882.
FT   VARIANT    2165   2165       R -> H (in dbSNP:rs5745068).
FT                                /FTId=VAR_020283.
FT   VARIANT    2213   2213       A -> V (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069356.
FT   CONFLICT   2237   2237       S -> T (in Ref. 1; AAA15448/AAC19148).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2286 AA;  261518 MW;  A213AE1EA8437DEC CRC64;
     MSLRSGGRRR ADPGADGEAS RDDGATSSVS ALKRLERSQW TDKMDLRFGF ERLKEPGEKT
     GWLINMHPTE ILDEDKRLGS AVDYYFIQDD GSRFKVALPY KPYFYIATRK GCEREVSSFL
     SKKFQGKIAK VETVPKEDLD LPNHLVGLKR NYIRLSFHTV EDLVKVRKEI SPAVKKNREQ
     DHASDAYTAL LSSVLQRGGV ITDEEETSKK IADQLDNIVD MREYDVPYHI RLSIDLKIHV
     AHWYNVRYRG NAFPVEITRR DDLVERPDPV VLAFDIETTK LPLKFPDAET DQIMMISYMI
     DGQGYLITNR EIVSEDIEDF EFTPKPEYEG PFCVFNEPDE AHLIQRWFEH VQETKPTIMV
     TYNGDFFDWP FVEARAAVHG LSMQQEIGFQ KDSQGEYKAP QCIHMDCLRW VKRDSYLPVG
     SHNLKAAAKA KLGYDPVELD PEDMCRMATE QPQTLATYSV SDAVATYYLY MKYVHPFIFA
     LCTIIPMEPD EVLRKGSGTL CEALLMVQAF HANIIFPNKQ EQEFNKLTDD GHVLDSETYV
     GGHVEALESG VFRSDIPCRF RMNPAAFDFL LQRVEKTLRH ALEEEEKVPV EQVTNFEEVC
     DEIKSKLASL KDVPSRIECP LIYHLDVGAM YPNIILTNRL QPSAMVDEAT CAACDFNKPG
     ANCQRKMAWQ WRGEFMPASR SEYHRIQHQL ESEKFPPLFP EGPARAFHEL SREEQAKYEK
     RRLADYCRKA YKKIHITKVE ERLTTICQRE NSFYVDTVRA FRDRRYEFKG LHKVWKKKLS
     AAVEVGDAAE VKRCKNMEVL YDSLQLAHKC ILNSFYGYVM RKGARWYSME MAGIVCFTGA
     NIITQARELI EQIGRPLELD TDGIWCVLPN SFPENFVFKT TNVKKPKVTI SYPGAMLNIM
     VKEGFTNDQY QELAEPSSLT YVTRSENSIF FEVDGPYLAM ILPASKEEGK KLKKRYAVFN
     EDGSLAELKG FEVKRRGELQ LIKIFQSSVF EAFLKGSTLE EVYGSVAKVA DYWLDVLYSK
     AANMPDSELF ELISENRSMS RKLEDYGEQK STSISTAKRL AEFLGDQMVK DAGLSCRYII
     SRKPEGSPVT ERAIPLAIFQ AEPTVRKHFL RKWLKSSSLQ DFDIRAILDW DYYIERLGSA
     IQKIITIPAA LQQVKNPVPR VKHPDWLHKK LLEKNDVYKQ KKISELFTLE GRRQVTMAEA
     SEDSPRPSAP DMEDFGLVKL PHPAAPVTVK RKRVLWESQE ESQDLTPTVP WQEILGQPPA
     LGTSQEEWLV WLRFHKKKWQ LQARQRLARR KRQRLESAEG VLRPGAIRDG PATGLGSFLR
     RTARSILDLP WQIVQISETS QAGLFRLWAL VGSDLHCIRL SIPRVFYVNQ RVAKAEEGAS
     YRKVNRVLPR SNMVYNLYEY SVPEDMYQEH INEINAELSA PDIEGVYETQ VPLLFRALVH
     LGCVCVVNKQ LVRHLSGWEA ETFALEHLEM RSLAQFSYLE PGSIRHIYLY HHAQAHKALF
     GIFIPSQRRA SVFVLDTVRS NQMPSLGALY SAEHGLLLEK VGPELLPPPK HTFEVRAETD
     LKTICRAIQR FLLAYKEERR GPTLIAVQSS WELKRLASEI PVLEEFPLVP ICVADKINYG
     VLDWQRHGAR RMIRHYLNLD TCLSQAFEMS RYFHIPIGNL PEDISTFGSD LFFARHLQRH
     NHLLWLSPTA RPDLGGKEAD DNCLVMEFDD QATVEINSSG CYSTVCVELD LQNLAVNTIL
     QSHHVNDMEG ADSMGISFDV IQQASLEDMI TGGQAASAPA SYDETALCSN TFRILKSMVV
     GWVKEITQYH NIYADNQVMH FYRWLRSPSS LLHDPALHRT LHNMMKKLFL QLIAEFKRLG
     SSVIYANFNR IILCTKKRRV EDAIAYVEYI TSSIHSKETF HSLTISFSRC WEFLLWMDPS
     NYGGIKGKVS SRIHCGLQDS QKAGGAEDEQ ENEDDEEERD GEEEEEAEES NVEDLLENNW
     NILQFLPQAA SCQNYFLMIV SAYIVAVYHC MKDGLRRSAP GSTPVRRRGA SQLSQEAEGA
     VGALPGMITF SQDYVANELT QSFFTITQKI QKKVTGSRNS TELSEMFPVL PGSHLLLNNP
     ALEFIKYVCK VLSLDTNITN QVNKLNRDLL RLVDVGEFSE EAQFRDPCRS YVLPEVICRS
     CNFCRDLDLC KDSSFSEDGA VLPQWLCSNC QAPYDSSAIE MTLVEVLQKK LMAFTLQDLV
     CLKCRGVKET SMPVYCSCAG DFALTIHTQV FMEQIGIFRN IAQHYGMSYL LETLEWLLQK
     NPQLGH
//
